Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrassesco, María Sol-
dc.contributor.authorPezuk, Julia Alejandra-
dc.contributor.authorMorales, Andressa Gois-
dc.contributor.authorOliveira, Jaqueline Carvalho de-
dc.contributor.authorRoberto, Gabriela Molinari-
dc.contributor.authorSilva, Glenda Nicioli da-
dc.contributor.authorOliveira, Harley Francisco de-
dc.contributor.authorScrideli, Carlos Alberto-
dc.contributor.authorTone, Luiz Gonzaga-
dc.identifier.citationBRASSESCO, M. S. et al. In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors. Cancer Biology & Therapy, v. 14, p. 648–657, 2013. Disponível em:<> . Acesso em: 16 jun. 2017.pt_BR
dc.description.abstractDespite the improvements in neoadjuvant chemotherapy, the outcome of patients with advanced bladder cancer has changed very little over the past 30 years. In the present study we tested and compared the in vitro antitumor activities of four different inhibitors of Polo-like kinase 1 (PLK1) (BI 2536, BI 6727, GW843682X, and GSK461364), against 3 bladder carcinoma cell lines RT4, 5637 and T24. The impact on radiosensitivity and drug interactions in simultaneous treatments with cisplatin, methotrexate, and doxorubicin were also investigated. Our results showed that PLK1 inhibition prevented cell proliferation and clonogenicity, causing significant inhibition of invasion of tumor cells, though modest differences were observed between drugs. Moreover, all PLK1 inhibitors induced G2/M arrest, with the subsequent induction of death in all 3 cell lines. Drug interactions studies showed auspicious results for all PLK1 inhibitors when combined with the commonly used cisplatin and methotrexate, though combinations with doxorubicin showed mostly antagonistic effects. Comparably, the four PLK1 inhibitors efficiently sensitized cells to ionizing radiation. Our findings demonstrate that irrespective of the inhibitor used, the pharmacological inhibition of PLK1 constrains bladder cancer growth and dissemination, providing new opportunities for future therapeutic intervention. However, further laboratorial and preclinical tests are still needed to corroborate the usefulness of using them in combination with other commonly used chemotherapeutic drugs.pt_BR
dc.subjectBladder cancerpt_BR
dc.subjectCell linespt_BR
dc.titleIn vitro targeting of Polo-like kinase 1 in bladder carcinoma : comparative effects of four potent inhibitors.pt_BR
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
1,77 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.